In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Idorsia Ltd, with a price target of CHF6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ram Selvaraju has given his Buy rating due to a combination of factors, primarily the recent approval of aprocitentan in Switzerland, which marks a significant step for Idorsia despite the market’s small size. This approval adds to the drug’s existing authorizations in Europe, the UK, and the US, enhancing its commercial potential in treating resistant hypertension, a condition affecting a notable percentage of hypertensive patients who are not adequately managed by existing therapies.
Additionally, Selvaraju highlights the strategic commercialization efforts for Idorsia’s key products, such as daridorexant and aprocitentan, which are expected to drive significant revenue growth. The company’s focus on efficient marketing strategies and potential partnerships could further bolster its financial performance. The valuation of Idorsia, based on a discounted cash flow analysis, supports a price target of CHF6 per share, reflecting confidence in the company’s growth prospects despite inherent risks such as potential trial failures or delays in asset approvals.
According to TipRanks, Selvaraju is a 5-star analyst with an average return of 26.7% and a 56.36% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Bioxcel Therapeutics, Emergent Biosolutions, and BridgeBio Pharma.